Literature DB >> 4015713

In vitro inhibition of animal and higher plants 2,3-oxidosqualene-sterol cyclases by 2-aza-2,3-dihydrosqualene and derivatives, and by other ammonium-containing molecules.

A Duriatti, P Bouvier-Nave, P Benveniste, F Schuber, L Delprino, G Balliano, L Cattel.   

Abstract

2-Aza-2,3-dihydrosqualene and related molecules, a series of new compounds designed as analogues of the transient carbocationic high energy intermediate, occurring in the oxirane ring opening during the cyclization of 2,3-oxidosqualene, were tested in vitro as inhibitors of the microsomal 2,3-oxidosqualene cyclase of animals (rat liver) and of higher plants (maize, pea). These molecules proved to be good and specific inhibitors for the cyclases of both phyla. The inhibition is due to positively charged species and is sensitive to the steric hindrance around the nitrogen-atom. 4,4,10 beta-Trimethyl-trans-decal-3 beta-ol and 4,10 beta-dimethyl-trans-decal-3 beta-ol, which have previously been described (J.A. Nelson et al., J. Am. chem. Soc. 100, 4900 (1978] as inhibitors of the 2,3-oxidosqualene cyclase of chinese hamster ovary cells, were found to be non-competitive inhibitors of the rat liver microsomal enzyme and presented no activity towards the higher plants cyclases. Aza derivatives of these decalines (A. Rahier et al., Phytochemistry, in press), which were aimed to mimic the C-8 carbocationic intermediate occurring during later steps of the 2,3-oxidosqualene cyclization did not inhibit the cyclases. This result underlines the theoretical limitations of the high energy analogues concept in designing enzyme inhibitors. Amongst other molecules tested, 2,3-epiminosqualene was found to be a reversible, non-competitive inhibitor of the cyclases; similarly U18666A was a very potent inhibitor of the microsomal cyclases. In contrast AMO 1618, a known anticholesterolemic agent reported previously to act at the level of the 2,3-oxidosqualene cyclization step, was not found per se to act on the cyclases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015713     DOI: 10.1016/0006-2952(85)90578-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

1.  Selective Aster inhibitors distinguish vesicular and nonvesicular sterol transport mechanisms.

Authors:  Xu Xiao; Youngjae Kim; Beatriz Romartinez-Alonso; Kristupas Sirvydis; Daniel S Ory; John W R Schwabe; Michael E Jung; Peter Tontonoz
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

2.  Retinal structure and function in an animal model that replicates the biochemical hallmarks of desmosterolosis.

Authors:  S J Fliesler; M J Richards; C Miller; N S Peachey; R J Cenedella
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

3.  Comparison of effects of U18666A and enantiomeric U18666A on sterol synthesis and induction of apoptosis.

Authors:  Richard J Cenedella; Patricia S Sexton; Kathiresan Krishnan; Douglas F Covey
Journal:  Lipids       Date:  2005-06       Impact factor: 1.880

4.  Metabolism of 2(RS),3-epiminosqualene to 24(RS),25-epiminolanosterol byGibberella fujikuroi.

Authors:  W D Nes; E J Parish
Journal:  Lipids       Date:  1988-04       Impact factor: 1.880

Review 5.  Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes.

Authors:  Richard J Cenedella
Journal:  Lipids       Date:  2009-05-14       Impact factor: 1.880

6.  The squalene-2,3-epoxide cyclase as a model for the development of new drugs.

Authors:  L Cattel; M Ceruti; F Viola; L Delprino; G Balliano; A Duriatti; P Bouvier-Navé
Journal:  Lipids       Date:  1986-01       Impact factor: 1.880

7.  Inhibition of cholesterol synthesis by cyclopropylamine derivatives of squalene in human hepatoblastoma cells in culture.

Authors:  W A Van Sickle; M R Angelastro; P Wilson; J R Cooper; A Marquart; M A Flanagan
Journal:  Lipids       Date:  1992-03       Impact factor: 1.880

Review 8.  Sterol biosynthesis inhibitors: their current status and modes of action.

Authors:  E I Mercer
Journal:  Lipids       Date:  1991-08       Impact factor: 1.880

9.  Deficiency of niemann-pick type C-1 protein impairs release of human immunodeficiency virus type 1 and results in Gag accumulation in late endosomal/lysosomal compartments.

Authors:  Yuyang Tang; Ihid Carneiro Leao; Ebony M Coleman; Robin Shepard Broughton; James E K Hildreth
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

10.  Inhibition of sterol biosynthesis in Saccharomyces cerevisiae and Candida albicans by 22,23-epoxy-2-aza-2,3-dihydrosqualene and the corresponding N-oxide.

Authors:  G Balliano; P Milla; M Ceruti; L Carrano; F Viola; P Brusa; L Cattel
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.